MDM2 SNP309 accelerates colorectal tumour formation in women
暂无分享,去创建一个
A. Levine | L. Aaltonen | G. Bond | R. Bertorelle | P. Alhopuro | Arnold J Levine | Lauri A Aaltonen | Roberta Bertorelle | Pia Alhopuro | C. Menin | Chiara Menin | Gareth L Bond
[1] C. Amos,et al. p53 Polymorphism and Age of Onset of Hereditary Nonpolyposis Colorectal Cancer in a Caucasian Population , 2004, Clinical Cancer Research.
[2] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[3] D. Lane,et al. Improving cancer therapy by non-genotoxic activation of p53. , 2003, European journal of cancer.
[4] A. Levine,et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.
[5] M. von Knebel Doeberitz,et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC) , 2005, Journal of Medical Genetics.
[6] A. Levine,et al. MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.
[7] L. Aaltonen,et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.
[8] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[9] S. Zienolddiny,et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.
[10] R. Bertorelle,et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. , 2006, Journal of the National Cancer Institute.